Handbook of Clinical medicine

efa- virenz (CNS toxicity, association with suicidality  care in depression/anxiety, adverse lipid profi le). Other side-eff ects: rash, GI disturbance. • Integrase inhibitor: Dolutegravir, elvitegravir, raltegravir. Side-eff ects: rash, GI disturbance, insomnia. Monitor: adherence (see BOX ‘Adherence’), adverse eff ects (LFTs, glucose), virologi- cal response (viral load). CD4 counts guide prophylaxis of opportunistic infection (values may not correlate with virological response, use viral load preferentially). Adherence Adherence to ART is associated with drug resistance, disease progression, and death. Adherence support should be integral to ART provision. Assess: Ask about adherence in a non-judgemental way. Do not blame. Explain the reasoning behind your questions. Is non-adherence due to practical problems or healthcare beliefs? Be ready to address both. What help would your patient like? Intervene: Normalize the situation—doubts and concerns about ART are common. Find time for discussion/information. Address concerns. Simplify the dosage regi- men, off er a multicompartment medication system. Link the taking of medication to a regular daily activity. Discuss side-eff ects: what are the risks/benefi ts to changing dose or ART regimen? Resource-limited settings In many resource-limited settings, universal access to ART remains an objective yet to be achieved. ~50% of those in need of treatment for
